
Sign up to save your podcasts
Or


Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
By BMJ Group4
1515 ratings
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907

497 Listeners

36 Listeners

48 Listeners

5 Listeners

7 Listeners

6 Listeners

3 Listeners

2 Listeners

3 Listeners

9 Listeners

40 Listeners

14 Listeners

1 Listeners

48 Listeners

0 Listeners

6 Listeners

28,586 Listeners

500 Listeners

131 Listeners

3 Listeners

20 Listeners

16,920 Listeners

33,452 Listeners

9,241 Listeners

23 Listeners

27,558 Listeners

31 Listeners

4 Listeners

19,831 Listeners

2 Listeners

46 Listeners

0 Listeners

1,621 Listeners

681 Listeners